Sodium-glucose co-transporters (SGLTs) are a family of transmembrane receptors which are variably expressed in the kidney and intestine, and physiologically function in the control of cellular glucose uptake. For example, SGLT1 is responsible for almost all sodium-dependent glucose uptake in the small intestine and approximately 3% in the kidney. In contrast, SGLT2 accounts for more than 90% of glucose reabsorption from the glomerular ultrafiltrate. Since glucose reabsorption is sodium-dependent, SGLTs also play a crucial role in natriuresis, plasma osmolarity, and regulation of plasma volume.
Interest in SGLTs has increased since their inhibition has proven to be an effective glucose-lowering treatment strategy. Moreover, beyond glycemic control, SGLT2 inhibitors have been shown to cause a significant reduction in cardiovascular and renal morbidity, lower hospitalization rates for heart failure, and reduce progression of renal damage and albuminuria in patients with or without diabetes mellitus. SGLT2 inhibitors also seem to reduce blood pressure and benefit weight loss. Their clinical impact has been so important that they have been included not only in diabetes treatment guidelines but also in the treatment of chronic heart failure, and chronic kidney disease and albuminuria regardless of glycemic status. Numerous pharmacological mechanisms for these effects have been hypothesized, although no conclusive evidence is currently available.
The aim of this Special Issue is to provide an update on our current knowledge of the function of SGLTs. The goal of this work is to promote the development of new pharmacodynamic hypotheses, as well as examine the clinical impact of SGLT inhibition on cardiovascular and renal risk independent of the presence of diabetes mellitus.
Dr. Riccardo Nevola
Manuscripts should be submitted via our online editorial system at https://imr.propub.com by registering and logging in to this website. Once you are registered, click here to start your submission. Manuscripts can be submitted now or up until the deadline. All papers will go through peer-review process. Accepted papers will be published in the journal (as soon as accepted) and meanwhile listed together on the special issue website. Research articles, reviews as well as short communications are preferred. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office to announce on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts will be thoroughly refereed through a double-blind peer-review process. Please visit the Instruction for Authors page before submitting a manuscript. The Article Processing Charge (APC) in this open access journal is 2500 USD. Submitted manuscripts should be well formatted in good English.
Distinct Approaches to Inhibit Fructose-Induced Obesity
Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Markers of Vascular Damage
SGLT1: a Promising Drug Target for Cardiac Diseases
Effects of Sodium-Glucose Transporter 2 Inhibitors (SGLT2is) on Fracture Risk: a Meta-Analysis of Randomized Controlled Trials
Comparing and Contrasting the Effects of the SGLT Inhibitors Canagliflozin and Empagliflozin on the Progression of Retinopathy
Lakshini Y. Herat, Jennifer R. Matthews, Piroska E Rakoczy, *Markus P. Schlaich and *Vance B. Matthews
- Open Access ReviewSodium-Glucose Co-Transporters Family: Current Evidence, Clinical Applications and PerspectivesRiccardo Nevola, Angela Villani, Simona Imbriani, Maria Alfano, ... Luca RinaldiFront. Biosci. (Landmark Ed) 2023, 28(5), 103; https://doi.org/10.31083/j.fbl2805103 (registering DOI)5Downloads13Views
- Open Access ReviewSGLT2i in Patients with Type 1 Diabetes: Benefits, Risks, and Preventive StrategiesYujin Ma, Qian Zhao, Huifang Peng, David Lubasi Nalisa, ... Hongwei JiangFront. Biosci. (Landmark Ed) 2023, 28(5), 98; https://doi.org/10.31083/j.fbl280509825Downloads56Views
- Open Access Original ResearchAnti-Diabetic Drugs Inhibit Bulimia Induced ObesityZhu Li, Jia Jia, Han Hao, Shiyang Qiao, ... Biao XuFront. Biosci. (Landmark Ed) 2023, 28(5), 97; https://doi.org/10.31083/j.fbl28050975Downloads37Views
- Open Access Original ResearchComparing and Contrasting the Effects of the SGLT Inhibitors Canagliflozin and Empagliflozin on the Progression of RetinopathyLakshini Y. Herat, Jennifer R. Matthews, Elizabeth P. Rakoczy, Markus P. Schlaich, Vance B. MatthewsFront. Biosci. (Landmark Ed) 2023, 28(4), 83; https://doi.org/10.31083/j.fbl280408348Downloads168Views
- Open Access Original ResearchSodium-Glucose Cotransporter 2 Inhibitors First Strategy Improve Decongestion in Patients with Symptomatic Heart Failure and Reduced Ejection Fraction When Compared to Angiotensin Receptor Neprilysin Inhibitor First StrategyWei-Chieh Lee, Wei-Ting Chang, Chon-Seng Hong, Chia-Te Liao, ... Jhih-Yuan ShihFront. Biosci. (Landmark Ed) 2023, 28(4), 81; https://doi.org/10.31083/j.fbl280408170Downloads164Views
- Open Access Original ResearchDetermining the Role of SGLT2 Inhibition with Dapagliflozin in the Development of Diabetic RetinopathyLakshini Y. Herat, Jennifer R. Matthews, Wei E. Ong, Elizabeth P. Rakoczy, ... Vance B. MatthewsFront. Biosci. (Landmark Ed) 2022, 27(12), 321; https://doi.org/10.31083/j.fbl2712321129Downloads362Views